Use of biologics in the era of COVID- 19: Where do we stand?

dc.creatorLee, Young Bin
dc.creatorHong, Seung Phil
dc.date.accessioned2020-09-30T15:08:48Z
dc.date.available2020-09-30T15:08:48Z
dc.date.created2020
dc.description.abstractThe novel coronavirus disease 2019 (COVID-19) has been spreading for more than 5 months since the World Health Organization declared the COVID-19 pandemic in March 2020. As of August 26, the pandemic had resulted in 23 million confirmed cases and 810,000 deaths worldwide. As the likelihood of prolonged spread without sudden termination of this situation increases, the topic of infection risk in patients treated with biologics is becoming crucial in the dermatologic field. Therefore, we conducted a PubMed search for articles reporting biologics exposure and reviewed guidelines on biologics use published during this pandemic.spa
dc.format.extent6 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.jdin.2020.07.009spa
dc.identifier.issn2666-3287spa
dc.identifier.otherhttps://doi.org/10.1016/j.jdin.2020.07.009spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/14016
dc.language.isoengspa
dc.publisherAmerican Academy of Dermatologyspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.localAbierto (Texto Completo)spa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleUse of biologics in the era of COVID- 19: Where do we stand?spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: